Salario de Farmacéutico en Massachusetts (2026)

Pharmacist OT classification varies by employer. Most retail pharmacy roles at CVS / Walgreens / Stop & Shop are FLSA-exempt under the professional exemption, so OT premium pay isn't standard. Hospital staff pharmacist roles at MGH / Brigham / BIDMC / Children's / Dana-Farber are typically FLSA-exempt as well, though shift-based per-diem and nights/weekends pay shift differentials. Industry biotech pharmacists at Moderna / Vertex / Biogen / Takeda are exempt salaried + RSU + bonus — the comp lever is total comp structure, not OT premium. Per-diem floater work at $80-110/hour in MA is the most common form of OT-eligible income for hospital pharmacists.

MA charges a flat 5% state income tax — simpler than MD's progressive structure. No local income tax (unlike MD's 2.81-3.20% county piggyback). At $145K MA pharmacist comp, MA effective = 5.0% = $7,250/year state — straightforward. Compared to MD pharmacist at $145K (4.95% MD + 3.20% county = $11,800/year combined): MA saves $4,500/year vs MD at this comp tier. Compared to TN (0%): MA costs $7,250/year more. The MA Fair Share / Millionaire's Surtax (4% additional on income over $1M, since 2023) does not affect typical pharmacist comp.

Real numbers for an MGH staff pharmacist at $148K base + per-diem floater $24K supplemental ($80/hr × 300 hrs/year) = $172K total. MA effective 5.0% × $172K = $8,600/year. Same comp in NH (5% on dividends/interest only, 0% on wages): $0/year wage tax. NH-vs-MA pharmacist tax gap: $8,600/year — which is why MGB / BIDMC / Brigham regularly recruit pharmacists from southern NH (Salem, Nashua, Manchester) commuting into Boston. The MA-vs-NH commuter math is the dominant arbitrage at the MA pharmacist tier; the Fair Share threshold ($1M) doesn't apply.

MA pharmacy clusters in three corridors. Boston / Longwood Medical Area (MGH, Brigham, BIDMC, Boston Children's, Dana-Farber, plus Tufts Medical Center) is the densest US academic medical pharmacy market by single-square-mile employer concentration. Cambridge biotech (Moderna, Vertex, Biogen, Takeda US, Novartis NIBR + adjacent Kendall Square ecosystem) anchors industry pharmacy at premium comp. Worcester (UMass Memorial Health + UMass Chan Medical School + smaller community hospitals) anchors central MA at lower COL than Boston. Plus statewide CVS / Walgreens / Stop & Shop retail.

Boston / Cambridge housing has appreciated sharply since 2020. Beacon Hill / Back Bay / South End premium tier $1.5M-$3M+, Brookline / Newton / Cambridge $1.2M-$2.5M+, Wellesley / Lexington / Concord $1.2M-$2.5M (top-rated school districts). South Shore (Hingham, Cohasset, Duxbury, Norwell) at $850K-$1.5M for waterfront access. North Shore (Marblehead, Beverly, Salem, Newburyport) at $700K-$1.2M for cheaper coastal lifestyle. MetroWest 128/495 corridor (Natick, Framingham, Westborough, Hopkinton) at $750K-$1.3M with shorter biotech-corridor commute. The southern NH commuter pattern (Salem, Nashua, Manchester) for MGH / Brigham / BIDMC staff is increasingly common given MA's 5% wage tax vs NH's 0%.

Many MA pharmacists retire in-state until they hit the estate-tax cliff. MA does fully exempt Social Security and partially exempts pension income depending on type. The estate-tax issue is acute: $2M MA exemption (raised from $1M only in October 2023; among the lowest in the US), 16% top rate. Senior pharmacists with $2M+ in 401(k) + IRA + home equity face material estate-tax planning. Pre-death relocation to NH / FL / TN / NV common for $3M+ asset bases. Common in-state retirement patterns: stay in MetroWest or South Shore, or migrate to Cape Cod (Barnstable, Falmouth, Sandwich) for waterfront; the $2M estate cliff drives more out-of-state relocation than MD's $5M.

Years 0-3 (new grad PharmD): $125-145K. PharmD + MA Board of Registration in Pharmacy licensure (NAPLEX + MPJE MA-specific). MCPHS University (founded 1823) graduates dominate the in-state pipeline; Northeastern + UMass-Boston also feed. Decision point: retail (CVS / Walgreens / Stop & Shop) vs hospital (MGB / BIDMC / Children's / Dana-Farber / Tufts) vs industry biotech entry (Moderna / Vertex / Biogen / Takeda / Novartis NIBR — typically requires PGY1 + industry fellowship or PhD overlay) vs federal (VA Boston GS-12 entry, $95-115K + locality). PSLF accumulating from year 1 at non-profits and federal.

Years 3-12 (established staff / specialty / industry track): $135-225K depending on lane. MGB / BIDMC / Children's staff pharmacist runs $135-155K + benefits. Specialty (oncology, ICU, cardiology, ID) with PGY2 + cert (BCOP, BCIDP, BCCCP, BCPS) adds $5-20K premium. Industry biotech (Moderna / Vertex / Biogen / Takeda / Novartis NIBR) reaches $145-225K + RSU + ESPP — the industry comp ceiling is uniquely high in MA. Maxing 403(b) + 457(b) at MGB academic centers is the central active-duty move on the hospital side; ESPP + RSU on the industry side.

Years 12+ (senior + management + retirement): $155-285K+ depending on track. Pharmacy manager at retail or hospital reaches $155-195K. VA Boston GS-14/15 reaches $145-180K base + 30.31% locality = $189-235K total + FERS pension. Industry biotech senior director / VP reaches $235-385K base + RSU + cash bonus. Many MA pharmacists retire to NH / FL / TN / NV pre-death given MA's $2M estate cliff. Common in-state retirement patterns: stay in MetroWest / South Shore, or migrate to Cape Cod or southern NH for the estate-tax delta.